ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 995

Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts

Wan-Hee Yoo1, Yunjung Choi 2, Eun-gyeong Lee 2, Chang-hoon Lee 3 and Myeung-Su Lee 3, 1Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical, Research Institute of Chonbuk National University Hospital, Jeonju, Korea, JeonJu, Republic of Korea, 2Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, JeonJu, Republic of Korea, 3Wonkwang University College of Medicine, Iksan, Republic of Korea

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Animal models, endoplasmic reticulum stress and 4-phenylbutyric acid, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Animal Models Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Several studies have recently revealed the pathological role of endoplasmic reticulum (ER) stress in the pathogenesis of inflammatory diseases. In addition, 4-phenylbutyric acid (4-PBA) was shown to exert potent pharmacological effects, including anti-inflammatory properties, via inhibition of ER stress. However, it is not known whether 4-PBA attenuates the severity of rheumatoid arthritis, which is most the common inflammatory arthritis.

The purpose of the present study was to investigate the effect of ER stress inhibition by 4-PBA on interleukin-1β-induced proliferation and the inflammatory response of rheumatoid synovial fibroblasts (RASFs) and determine whether the inhibition of ER stress by 4-PBA ameliorated experimentally induced arthritis. The potential underlying mechanisms of the therapeutic efficacy of 4-PBA were also investigated.

Methods: The proliferation of RASFs and expression of matrix metalloproteinases were evaluated in the presence of IL-1β with or without 4-PBA. The effect of 4-PBA on the phosphorylation of MAPK and the activation of NF-kB in IL-1β-stimulated RASFs was assessed. In an in vivo study, the effects of 4-PBA were investigated using DBA/1 mice with collagen-induced arthritis (CIA). Assessments of paw thickness, clinical score, micro-computed tomography imaging, histology of tibiotalar joints, and the inflammatory cytokine levels of joints extracts and serum were used to determine the therapeutic effect of 4-PBA.

Results: In vitro, 4-PBA inhibited the proliferation and expression of IL-1β-stimulated RASFs and matrix metalloproteinases (MMP-1 and MMP-3) through the suppression of both the phosphorylation of MAPKs and NF-kB in IL-1β-stimulated RASFs. The intraperitoneal administration of 4-PBA markedly attenuated the severity of arthritis in CIA mice. 4-PBA treatment ameliorated joint swelling, the degree of bone erosion and destruction, and decreased the level of inflammatory cytokines (IL-6 and IL-1β) and matrix metalloproteinases (MMP-3 and Cox-2). Furthermore, remarkable improvements in histopathological findings occurred in 4-PBA-treated mice.

Conclusion: These findings suggested that 4-PBA could attenuate the severity of arthritis in CIA mice through partially blocking the phosphorylation of MAPKs and the activation of NF-κB in RASFs. Thus, through the inhibition of ER stress, 4-PBA may be a potent agent for the treatment of RA.


Disclosure: W. Yoo, None; Y. Choi, None; E. Lee, None; C. Lee, None; M. Lee, None.

To cite this abstract in AMA style:

Yoo W, Choi Y, Lee E, Lee C, Lee M. Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/inhibition-of-endoplasmic-reticulum-stress-using-4-phenylbutyric-acid-ameliorates-the-severity-of-collagen-induced-arthritis-in-mice-via-attenuation-of-proliferation-and-inflammatory-responses-of-syno/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-endoplasmic-reticulum-stress-using-4-phenylbutyric-acid-ameliorates-the-severity-of-collagen-induced-arthritis-in-mice-via-attenuation-of-proliferation-and-inflammatory-responses-of-syno/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology